George Goldsmith

Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and business developments. Numbers on 30 September 2022 show: Cash and cash equivalents totaled $...

COMPASS Pathways plc (NASDAQ: CMPS) released financial results for the second quarter 2022 and gave an update on recent progress across its business. Q2 2022 Financial Highlights Net loss for the three months ended 30 June 2022 was $21.0 million, or $0.50 loss per share, compared with $17.5...

Two companies in the psychedelics space have chosen new chief executive officers: COMPASS Pathways (NASDAQ: CMPS) has chosen Kabir Nath, and Small Pharma will be now led by George Tziras. Compass Pathways Adds Kabir Nath On Board Nath will effectively become chief executive officer...

COMPASS Pathways plc (NASDAQ: CMPS) has announced the formation of a long-term partnership with the South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry, Psychology & Neuroscience at King’s College London. The aim of this collaboration is to launch The...

Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: CMPS) revealed Friday that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective as of market open on Monday, Dec. 20. “We are proud to announce our addition to the esteemed...

Shares from psychedelics unicorn Compass Pathways (NASDAQ: CMPS) are soaring in anticipation of the data being created by the company’s phase 2 trial with the psychedelic psilocybin. Adding to the excitement, Compass announced on Wednesday the launch of a new program using the...

Compass Pathways (Nasdaq: CMPS), a biotech company in the psychedelics space, announced it has completed a key milestone on its path to obtaining FDA approval for psilocybin in the treatment of depression. The company reported that it had completed psilocybin administration to all 216...

Compass Pathways (NASDAQ: CMPS), a company researching psychedelics for mental health treatment, released its financial statement for the first quarter of 2021. The company, currently pushing psilocybin through a phase 2b clinical trial, highlighted the issuing of two new patents and a post-quarter...

Compass Secures 2 New Patents In the midst of a public debate about the right use of patents in the psychedelics sector, Compass Pathways (NASDAQ: CMPS) was granted two new patents by the US Patent and Trademark Office. Compass came under scrutiny last month for applying to a series of...

Compass Launches Center Of Excellence Compass Pathways (NASDAQ: CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland. This “clinic model” will study and...

Welcome to Psyched, a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. CaaMTech Launches Research Collaboration With National Institutes of Health...